Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades.

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significant advancement in pain management,

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.